MONALEESA-3 Update Confirms Ribociclib–Fulvestrant OS Benefit For Advanced Breast Cancer
From ESMO Breast Cancer 2022:
For patients with hormone receptor-positive, HER2-negative advanced breast cancer, the addition of ribociclib to fulvestrant continues to significantly improves overall survival after more than 70 months